Core Insights - Evolent Health reported a revenue of $468.72 million for the quarter ended December 2025, reflecting a year-over-year decline of 27.5% [1] - The company's EPS for the same period was $0.08, compared to -$0.02 a year ago, indicating a positive turnaround [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $469.22 million, resulting in a surprise of -0.11%, while the EPS exceeded expectations by 28% [1] Financial Performance - Evolent Health's shares have decreased by 25.3% over the past month, contrasting with the Zacks S&P 500 composite's decline of only 1% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Key Metrics - Average PMPM Fees / Revenue per Case for Performance Suite was $13.87, slightly below the estimated $14.14 [4] - Average Lives on Platform for Cases reached 14 thousand, slightly above the estimated 13.86 thousand [4] - Total Revenue by product type for Performance Suite was $269.46 million, which is a 41% decline compared to the year-ago quarter [4] - Total Revenue by product type for Specialty Technology and Services Suite was $95.74 million, showing a year-over-year increase of 16.3% [4]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $469 million and Adjusted EBITDA of $37.8 million, exceeding the midpoint of guidance [25] - The full year 2025 revenue, after adjusting for the ACO divestiture, was $1.7 billion, with Adjusted EBITDA approximately $141 million [25] - The Medical Expense Ratio (MER) for 2025 was 89%, showing an improvement of nearly 700 basis points compared to 2024 [19][25] - The company forecasts 2026 revenue at $2.5 billion, representing a growth of approximately 30% [10] Business Line Data and Key Metrics Changes - Oncology is expected to contribute approximately 65% of total revenue in 2026, up from 36% in 2025 [5] - The MER for Q4 2025 was 95%, driven by out-of-period true-ups, but underlying medical trends remained stable [25][19] - The company anticipates that the 2026 cohort will run at 103% MER, while the total cohort is expected to run at approximately 93% [19][34] Market Data and Key Metrics Changes - The managed care industry is undergoing a multi-year margin recovery cycle, leading health plans to seek solutions that lower costs while improving quality [21] - The company is experiencing a contraction in exchange membership, which is expected to create a $40 million headwind in 2026 [37] Company Strategy and Development Direction - The company aims to capture market share through new partnerships and is focused on expanding its customer footprint under strong terms [22] - The strategy includes leveraging technology and AI to improve operational efficiency and reduce costs [23] - The company is committed to prioritizing debt paydown as its primary capital allocation focus [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate near-term challenges and capitalize on substantial opportunities [44] - The company expects a significant tailwind from the maturation of 2026 contracts and anticipates a return to growth in exchange membership over time [21][16] Other Important Information - The company has successfully transitioned approximately 90% of Performance Suite revenue to the new Enhanced Performance Suite model [8] - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [20] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, and the initial reserves are more conservative due to new data flow and implementation challenges [46][47] Question: What are the early indicators for new membership this year? - Management noted that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [50][51] Question: How should we model stock-based compensation and capital deployment for 2026? - Management indicated that stock-based compensation should remain consistent with past trends and emphasized a focus on deleveraging while being open to liability management opportunities [54][56] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, with no significant changes anticipated compared to 2025 [60][62] Question: What are the swing factors in the EBITDA guidance? - Management highlighted that the Medical Expense Ratio (MER) is a significant swing factor, along with the potential for accelerated savings from clinical programs [80]

Financial Data and Key Metrics Changes - Q4 2025 revenue totaled $469 million, with Adjusted EBITDA at $37.8 million, exceeding the midpoint of guidance [25] - For fiscal year 2025, baseline revenue was $1.7 billion, and Adjusted EBITDA would have been approximately $141 million [25] - The Medical Expense Ratio (MER) for 2025 was 89%, with Q4 MER at 95%, driven by out-of-period true-ups [26][19] - The company expects 2026 revenue to reach $2.5 billion at the midpoint, representing a growth of approximately 30% [10] Business Line Data and Key Metrics Changes - Oncology is projected to contribute approximately 65% of company revenue in 2026, up from 36% in 2025 [5] - The 2026 Performance Suite launches are expected to generate approximately $900 million in revenue, representing 37% of total 2026 revenue [11] - The company anticipates a MER of approximately 93% for 2026, compared to 89% in 2025 [34] Market Data and Key Metrics Changes - The managed care industry is undergoing a multi-year margin recovery cycle, leading health plans to seek solutions to lower costs while improving quality [21] - The company is experiencing a contraction in exchange membership, which presents near-term headwinds [21] Company Strategy and Development Direction - The company aims to capture market share through new partnerships and is focused on disciplined capital allocation [4] - Evolent is transitioning contracts to the Enhanced Performance Suite model, which includes revenue rate adjustments and downside protections [8] - The company is leveraging technology and AI to improve operational efficiency and reduce costs [23] Management's Comments on Operating Environment and Future Outlook - Management is confident in the growth trajectory for 2026, despite near-term challenges from exchange membership declines [16] - The company believes it is well-positioned to deliver earnings growth as new contracts mature and operational initiatives take effect [36] - Management emphasizes a conservative approach to reserving for new contracts, which is expected to create temporary headwinds in 2026 [46] Other Important Information - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [20] - A significant non-cash goodwill impairment was recorded due to market valuation declines, which does not impact EBITDA or cash flow [27] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, leading to a more conservative approach initially due to new data flow and implementation challenges [46][47] Question: What are the early indicators for new membership this year? - Management noted that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [50][51] Question: How should we model stock-based compensation and capital deployment for 2026? - Management indicated that stock-based compensation will remain consistent with past levels and emphasized a focus on deleveraging while being open to liability management opportunities [54][56] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, similar to 2025, with various mechanisms in contracts to adjust for changes in acuity [60][61] Question: What are the swing factors in the EBITDA guidance? - Management highlighted that MER is a significant factor, along with the potential for accelerated savings from clinical programs [80]

Financial Data and Key Metrics Changes - Q4 2025 revenue totaled $469 million, with Adjusted EBITDA at $37.8 million, exceeding the midpoint of guidance [24] - For fiscal year 2025, baseline revenue was $1.7 billion, and Adjusted EBITDA would have been approximately $141 million after adjusting for the ACO divestiture [24] - The Medical Expense Ratio (MER) for 2025 was 89%, improving by nearly 700 basis points compared to 2024 [18][24] - The company forecasts 2026 revenue at $2.5 billion, representing approximately 30% growth, with Adjusted EBITDA guidance at $125 million [9][30] Business Line Data and Key Metrics Changes - Oncology is expected to contribute approximately 65% of total revenue in 2026, up from 36% in 2025, indicating a significant focus on this area for growth [4] - The MER for the fourth quarter was 95%, driven by out-of-period true-ups, but underlying medical trends remained stable [24][25] - The company anticipates that the existing Performance Suite business will contribute $35 million of additional profitability despite revenue declines from exchange-related membership contraction [30] Market Data and Key Metrics Changes - The managed care industry is experiencing a multi-year margin recovery cycle, leading health plans to seek solutions that lower costs while improving quality [20] - The company is facing near-term headwinds due to contracting membership in the industry, which is expected to impact revenue [20] - The Specialty TNS business is projected to deliver modest underlying growth in 2026, despite significant headwinds from exchange membership declines [30] Company Strategy and Development Direction - The company aims to capture market share through new partnerships while maintaining a disciplined approach to underwriting [20] - Evolent is focusing on enhancing operational efficiency through technology and AI, with a goal to automate 80% of baseline authorization volume [21] - The company is committed to prioritizing debt paydown as its primary capital allocation focus while investing in product and technology for long-term growth [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate near-term challenges and capitalize on substantial opportunities in the market [42] - The outlook for 2026 includes expectations for strong Performance Suite growth, with revenue reaching an all-time high, despite temporary headwinds from reserving methodologies [28] - Management noted that the demand for Evolent's services has never been greater, with a clear strategy to expand customer footprint under strong terms [20] Other Important Information - The company ended 2025 with net debt of $782 million, below the expected range, and has no maturities until late 2029 [19] - A large non-cash goodwill impairment was recorded due to market valuation declines, which does not impact EBITDA or cash flow [26] Q&A Session Summary Question: Can you help us understand the rationale behind the conservative approach to reserving? - Management explained that new contracts require different levels of reserves, leading to a more conservative approach initially due to new data flow and implementation [44][45] Question: What are the early indicators for new membership behavior this year? - Management indicated that early indicators are consistent with a 40% reduction in exchange membership, primarily due to clients proactively stepping away from risk pools [48][49] Question: How should we model stock-based compensation and capital deployment for 2026? - Management advised that stock-based compensation should remain consistent with past assumptions and emphasized a focus on deleveraging while being open to liability management opportunities [52][55] Question: Can you clarify the expected oncology cost trends for 2026? - Management stated that oncology trends are expected to remain stable, with no significant changes anticipated compared to 2025 [58][60] Question: What are the swing factors affecting the high and low ends of the EBITDA guidance? - Management highlighted that the Medical Expense Ratio (MER) is a significant factor, along with the potential for accelerated savings from clinical programs [77][78]

Evolent Health, Inc. Fourth Quarter 2025 Results February 24, 2026 Evolent | Confidential—Do not distribute | 1 Safe Harbor Statement Certain statements made in this report and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, ind ...

Core Insights - Evolent Health, Inc. reported a revenue of $468.7 million for Q4 2025 and $1.88 billion for the full year 2025, with a projected revenue growth of approximately 30% for 2026 [1][2] - The company experienced a net loss of $429.1 million in Q4 2025 and $579.4 million for the full year, with a net loss margin of 91.6% for Q4 and 30.9% for the year [1][3] - Adjusted EBITDA for Q4 2025 was $37.8 million, maintaining an adjusted EBITDA margin of 8.1% for both Q4 and the full year [1][3] Financial Performance - Revenue for Q4 2025 was $468,719,000, down from $646,542,000 in Q4 2024; full-year revenue was $1,876,229,000 compared to $2,554,741,000 in 2024 [3][4] - The cost of revenue for Q4 2025 was $371,466,000, leading to an operating loss of $408,231,000 for the quarter [3][4] - Selling, general, and administrative expenses increased to $72,656,000 in Q4 2025 from $47,701,000 in Q4 2024 [3][4] Customer Metrics - Average lives on the Performance Suite platform were 6,475 for Q4 2025, with a total of 40,038 average unique members [1][2] - The average PMPM fee for the Performance Suite was $13.87 in Q4 2025, compared to $14.48 in Q4 2024 [1][2] Business Outlook - The company expects full-year 2026 revenue to be in the range of $2.4 billion to $2.6 billion, with Adjusted EBITDA projected between $110 million and $140 million [2][3] - Evolent plans to invest approximately $25 million to $35 million in capitalized software development during 2026 [2][3] Market Position - Evolent continues to grow its market share and customer retention rates, indicating strong demand for its complex specialty care solutions [1][2] - The company aims to assist health plans in balancing quality and affordability, particularly in oncology, cardiology, and musculoskeletal conditions [1][2]

Evolent Health Conference Call Summary Company Overview - **Company**: Evolent Health - **Industry**: Managed Care and Healthcare IT - **Focus Areas**: Specialty care management, particularly in oncology, cardiology, and musculoskeletal conditions [3][4] Key Financial Insights - **Revenue Composition**: Two-thirds of Evolent's revenue is linked to the ACA Marketplace and Medicaid, while about one-third is from Medicare Advantage [6] - **2025 Guidance**: Evolent reiterated its 4Q and 2025 guidance, with adjusted EBITDA expected to be $149 million, including $10 million from an asset being divested [32][33] - **Performance Suite**: Expected to generate about 80% of adjusted EBITDA from tech and services, and 20% from risk-based Performance Suites [19][33] Cost Trends and Utilization - **Cost Trends**: Oncology cost trend is under 11%, while cardiology trends are higher due to benefits rush ahead of premium increases [4] - **Impact on Specialty Cost**: Evolent uses risk pool adjustments to isolate its impact on specialty cost trends, with a growing pipeline of Medicare Advantage business [6][10] Value Creation and Cost Savings - **Evidence-Based Pathways**: Evolent aims to increase adherence to evidence-based care from 65% to about 85%, which reduces costs by ensuring the right treatment is provided initially [9][10] - **Cost Categories**: In oncology, 80% of costs are in therapeutics, with significant savings opportunities in matching therapies to patients. In cardiology, savings come from preventing surgical interventions [12][14] Contractual Protections and Market Dynamics - **Contractual Protections**: Evolent has secured protections around case mix and drug pricing in 90% of contracts, allowing for better risk management [22][24] - **Market Environment**: Health plans are more willing to negotiate favorable terms due to financial pressures, allowing Evolent to secure better contracts [23][25] Future Expectations - **2026 Revenue Outlook**: Evolent expects $750 million in new Performance Suite annual contract value (ACV) with $550 million anticipated to hit in 2026 [29][31] - **EBITDA Expectations**: Minimal EBITDA contribution expected from new contracts in 2026, with a target of reaching a 10% margin by mid to late 2028 [31] Membership and Market Challenges - **Membership Trends**: Declines in Medicaid membership and Medicare Advantage membership are impacting revenue, with expectations of a 40-60% shrinkage in ACA Marketplace revenue [36][42] - **Operational Investments**: Evolent invested $10 million in AI and efficiency improvements to enhance clinical operations and reduce costs [37] Strategic Decisions - **Divestiture of ECP**: Evolent decided to divest its ECP business to focus on its core specialty business, which is expected to grow significantly [49][50] - **Use of Proceeds**: Proceeds from the divestiture will be used to pay down high-interest debt, improving cash flow conversion and targeting a leverage ratio of about 5.5 times by year-end [51][52] Conclusion Evolent Health is strategically positioned in the managed care sector, focusing on specialty care management with a strong emphasis on cost reduction through evidence-based practices. The company is navigating market challenges while securing favorable contractual terms and investing in operational efficiencies to drive future growth.

Financial Data and Key Metrics Changes - Q3 revenue reached $479.5 million, exceeding expectations and at the top of the guidance range, with full-year revenue expected between $1.87 billion and $1.88 billion [3][18] - Adjusted EBITDA for Q3 was $39 million, representing a 23% year-over-year growth [8][19] - The company ended the quarter with $116.7 million in cash and equivalents, and net debt of $910 million [20][22] Business Line Data and Key Metrics Changes - The Performance Suite and Technology and Services Suite contributed to revenue growth, with new contracts expected to add over $550 million in 2026 revenue [4][6] - The specialty Performance Suite care margin was approximately 7%, consistent with year-to-date performance [19] Market Data and Key Metrics Changes - The company anticipates a contraction of approximately 3% in Medicare Advantage membership for 2026, with a significant decline expected in the exchange market [14][15] - Revenue from exchanges this year is around $360 million, split evenly between the Performance Suite and Technology and Services [34][35] Company Strategy and Development Direction - The company is focused on organic growth, margin expansion, and disciplined capital allocation, with a long-term goal to auto-approve over 80% of baseline authorization volume [8][9] - A strategic partnership with American Oncology Network aims to enhance provider alignment and improve cancer care without relying on utilization management [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capture market share despite a challenging operating environment, particularly in oncology [10][14] - The outlook for 2026 adjusted EBITDA is uncertain due to potential membership declines in key markets, but new contracts are expected to provide significant growth opportunities [15][17] Other Important Information - The company is transitioning its CFO role, with Mario Ramos set to join as the new CFO [24][25] - The divestiture of Evolent Care Partners is expected to close later this year, with proceeds used to reduce debt [9][22] Q&A Session Summary Question: Discussion on new contract wins and peak margins - Management confirmed that all new contracts are under the enhanced performance suite, with a reasonable mature margin target of around 10% [26][27][29] Question: Factors affecting 2026 EBITDA - Key factors include growth, cost structure efficiencies, and membership trends, with membership being the most uncertain variable [30][31][32] Question: MA growth assumptions for enrollment next year - Management noted that if current partners gain market share, it would positively impact revenue, particularly in the Technology and Services Suite [33] Question: Impact of HIX subsidies expiration - Management expressed confidence in pricing for 2026, with protections in contracts to mitigate acuity shifts [34][36] Question: Oncology trends and their progression - Oncology trends have remained stable throughout the year, with a slight increase in utilization noted in exchanges [37] Question: Pipeline pacing and go-live timing - The demand remains significant, and there is potential for new contracts to go live in 2026 [38] Question: Adversity in exchanges and membership impact - The benefits rush is primarily seen in cardiology, with a conservative approach taken for trend acceleration in the exchange line of business [40][41] Question: Product development and oncology navigation solution - The navigation solution is expected to expand into more markets, with a focus on improving care quality and affordability [46][48] Question: Revenue generation from the American Oncology partnership - The partnership aims to improve quality and reduce costs, with potential indirect revenue generation through payer interest [49]

Financial Performance - Revenue reached $479.5 million, reflecting an 8% sequential increase, driven by new launches in Performance Suite and Specialty Tech & Services[6] - Adjusted EBITDA was $39.0 million, a 23% year-over-year growth[6] - The company narrowed its revenue outlook for 2026 to between $1.87 billion and $1.88 billion[6] - Adjusted EBITDA outlook narrowed to between $144 million and $154 million[6] Capital Allocation - Evolent Health had $116.7 million in cash and cash equivalents as of September 30, 2025, with $47.5 million in revolver availability[6] - The company issued $166.8 million of 4.50% 2031 Notes and repaid $167.4 million of 2025 Notes[6] - Evolent repurchased 4.4 million shares of common stock for $40.0 million[6] - Exchanged $175.0 million of Series A Preferred Stock for second lien term loan on similar terms, with interest now tax deductible[6] - Period-end net leverage was 6.7x on LTM Adjusted EBITDA of $136.0 million[6] Business Growth - Announced two new revenue arrangements, one in the Performance Suite and one in the Technology and Services Suite, bringing YTD total to 13, forecasting approximately $2.5 billion for 2026[6]

Core Insights - Evolent Health, Inc. reported strong financial results for Q3 2025, achieving revenue of $479.5 million, which is a decrease from $621.4 million in Q3 2024, but the company is optimistic about future growth with a preliminary revenue forecast of $2.5 billion for 2026 [2][9][14] - The company added two new customer agreements in the quarter, bringing the total for the year to thirteen, and expects to generate over $750 million in new annualized revenue in 2026 [3][4] - Evolent's Adjusted EBITDA for Q3 2025 was $39.0 million, up from $31.8 million in Q3 2024, indicating improved operational efficiency [2][11] Financial Performance - Revenue for the three months ended September 30, 2025, was $479.5 million, down from $621.4 million in the same period last year [9] - The net loss attributable to common shareholders was $26.9 million, an improvement from a loss of $31.2 million in Q3 2024, resulting in a net loss margin of 5.6% compared to 5.0% [9][10] - Adjusted EBITDA increased to $39.0 million with an adjusted EBITDA margin of 8.1%, up from 5.1% in the prior year [2][11] Customer and Market Developments - Evolent signed two new revenue agreements in Q3 2025, contributing to a total of thirteen new contracts for the year [3][4] - A new partnership with a large regional Blues plan will implement Evolent's Performance Suite for Oncology, covering over 650,000 members [5] - The company continues to experience strong demand for its complex specialty care solutions due to rising medical costs impacting health plans [2] Leadership Changes - Mario Ramos has been appointed as the new Chief Financial Officer effective January 1, 2026, bringing extensive experience from CVS Health and WellBe Senior Medical [6][7] - John Johnson will transition to the role of Chief Strategy Officer, and Emily Rafferty will become Executive Vice President, Customer Success [7] Business Outlook - For Q4 2025, Evolent expects revenue to be in the range of $462 million to $472 million, with adjusted EBITDA projected between $30 million and $40 million [13] - The full-year revenue forecast for 2025 is approximately $1.87 billion to $1.88 billion, with adjusted EBITDA expected to be between $144 million and $154 million [14][15]